A Clinical Trial to Evaluate Efficacy and Safety of Elagolix Tablets in Women With Moderate or Severe Endometriosis-associated Pain - Trial NCT06076486
Access comprehensive clinical trial information for NCT06076486 through Pure Global AI's free database. This Phase 3 trial is sponsored by Nanjing Chia-tai Tianqing Pharmaceutical and is currently Recruiting. The study focuses on Endometriosis. Target enrollment is 330 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Nanjing Chia-tai Tianqing Pharmaceutical
Timeline & Enrollment
Phase 3
Sep 14, 2023
Sep 30, 2026
Primary Outcome
Percentage of responders of dysmenorrhea (DYS) at week 12,Percentage of responders of Non-Menstrual Pelvic Pain (NMPP) at week 12
Summary
This is a phase 3, multicenter, double-blind, placebo-controlled, randomized study to
 evaluate the efficacy and safety of elagolix tablets versus placebo in premenopausal women
 with moderate or severe endometriosis-associated pain.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06076486
Non-Device Trial